PPARγ 배위자에 의해 유도된 종양성장 억제와 비장세포의세포 살해능 증가
PPARγ Ligand-Induced Decrease of in vivo Tumor GrowthAccompanied by Increased Cytolytic Activity of Splenocytes
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background : Recent studies have proposed the use of peroxisome proliferator activated receptor-γ (PPARγ) ligands as new chemotherapeutic agents for human malignant tumors. However the in vivo mechanism of PPARγ ligands on cellular toxicity is not clear. Therefore we examined the anti-tumor effects of the PPARγ ligand, rosiglitazone (ROS), in animal models. Methods : To evaluate the effect of RSO on splenocytes, an in vitro and in vivo study was performed. Cytolytic activity was measured by use of a 51Cr release assay. The splenic natural killer (NK) cell population and effector-target conjugation were measured by flow cytometric analysis. Results : In 9L glioma bearing rats, 30 mg/kg/d of ROS treatment induced a significant decrease of subcutaneous tumor growth accompanied by an increased cytolytic activity of splenocytes and of the splenic NKR-P1bright/CD3- NK cell population. In normal rats, systemic administration of ROS also increased the cytolytic activity of splenocytes, the splenic NK cell population, and effector-target conjugation. Moreover, we found that a concentration of 20 μM ROS caused an increase in the cytolytic activity of splenocytes, and a concentration of 50 μM ROS increased effector-target conjugation in vitro. Conclusion : These results suggest that increased splenic cytolytic activity and NK cell population may contribute to the anti-tumor effects of PPARγ ligands in vivo. However, the roles of NK cells in the PPARγ ligand- induced anti-tumor activity should be further investigated.
참고문헌 (30)
- Kliewer SA, "Evans RM. Convergenceof 9-cis retinoic acid and peroxisome proliferator signallingpathways through heterodimer formation of their receptors. Nature1992", umeso(k), pp.771~4
- Mangelsdorf DJ, "The nuclear receptor superfamily: the second decade", 83, pp.835~839 (1995)
- Haydon RC, "Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma", 8, pp.1288~1294 (2002)
- "Peroxisome proliferator- activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer", 23, pp.100~108 (2004)
- "Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14) (12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells", 165, pp.6941~6948 (2000)
- "Expression of the peroxisome proliferator- activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein", 95, pp.7614~7619 (1998)
- "PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity", 19, pp.465~471 (2001)
- "Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor", tonto(z p), pp.1147~56
- "Troglitazone inhibits growth of MCF- 7 breast carcinoma cells by targeting G1 cell cycle regulators", 286, pp.916~922 (2001)
- "Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines", 95, pp.2243~2251 (2002)
- "Peroxisome proliferator- activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells", 104, pp.3276~3284 (2004)
- "PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis", 110, pp.923~932 (2002)
- "p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone", 156, pp.106~112 (1999)
- "Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL", 6J-APCMin, pp.1998, 4[DOI]
- "Troglitazione affects survival of human osteosarcoma cells", 98, pp.344~351 (2002)
- "Activators of the nuclear receptor PPARgamma enhance colon polyp formation", 4, pp.1058~1061 (1998)
- "Natural killer cells and cancer", 77, pp.1226~1243 (1996)
- "Tumor cell recognition by natural killer cells", 12, pp.57~61 (2002)
- "Natural killer cells and natural killer T cells", 43, pp.1204~1217 (2000)
- "Koo GC. Depletion of naturalkiller cells in mice by monoclonal antibody to NK-1.1. Reductionin host defense against malignancy without loss of cellular or humoralimmunity. J Immunol 1987", pp.4539~44
- "PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines", 391, pp.82~86 (1998)
- "The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation", 391, pp.79~82 (1998)
- "Herberman RB. In vitro augmentation of rat naturalkiller", pp.1581~5
- "NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function", 56, pp.3516~3525 (1996)
- "Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines", 139, pp.67~75 (2003)
- "Matsuura H. Progressive splenomegaly withincreasing extramedullary haematopoiesis in subcutaneous 9L-gliomabearing rats. Int J Exp Pathol 1993", pp.73~7
- "Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis", 7, pp.83~88 (1998)
- "Hiserodt JC. Mechanisms of target cell killing by naturalkiller cells. Curr Opin Immunol 1989", pp.39~42
- "Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT", 275, pp.4541~4544 (2000)
- "Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival", 277, pp.31781~31788 (2002)